Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon E Frey

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|March 2, 2002
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022AKalpana Gupta, Michael Hudgens, Lawrence Corey, et al.
Vaccine|December 15, 2015
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccineInnocent N Mbawuike, Robert L Atmar, Shital M Patel, et al.
Vaccine|December 3, 2014
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsSharon E Frey, David I Bernstein, Rebecca C Brady, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports|January 8, 2021
Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020Mary J Choi, Caitlin M Cossaboom, Amy N Whitesell, et al.
Vaccine|March 4, 2017
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trialLisa A Jackson, Sharon E Frey, Hana M El Sahly, et al.
Vaccine|November 11, 2008
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trialPaul Spearman, Spyros Kalams, Marnie Elizaga, et al.
Vaccine|January 11, 2011
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsMichael C Keefer, Sharon E Frey, Marnie Elizaga, et al.
JAMA|October 8, 2014
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trialRobert B Belshe, Sharon E Frey, Irene L Graham, et al.
Vaccine|July 29, 2017
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical TrialMark J Mulligan, Jack T Stapleton, Wendy A Keitel, et al.
The Journal of Infectious Diseases|February 2, 2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Alicia Sato, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Journal of Acquired Immune Deficiency Syndromes (1999)|March 2, 2002
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022AKalpana Gupta, Michael Hudgens, Lawrence Corey, et al.
Vaccine|December 15, 2015
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccineInnocent N Mbawuike, Robert L Atmar, Shital M Patel, et al.
Vaccine|December 3, 2014
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsSharon E Frey, David I Bernstein, Rebecca C Brady, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports|January 8, 2021
Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020Mary J Choi, Caitlin M Cossaboom, Amy N Whitesell, et al.
Vaccine|March 4, 2017
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trialLisa A Jackson, Sharon E Frey, Hana M El Sahly, et al.
Vaccine|November 11, 2008
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trialPaul Spearman, Spyros Kalams, Marnie Elizaga, et al.
Vaccine|January 11, 2011
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsMichael C Keefer, Sharon E Frey, Marnie Elizaga, et al.
JAMA|October 8, 2014
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trialRobert B Belshe, Sharon E Frey, Irene L Graham, et al.
Vaccine|July 29, 2017
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical TrialMark J Mulligan, Jack T Stapleton, Wendy A Keitel, et al.
The Journal of Infectious Diseases|February 2, 2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Alicia Sato, et al.
Pageof 12